-
-
EMA approves interferon beta treatments, including Rebif (interferon beta-1a), for relapsing MS patients during pregnancy and breastfeeding
-
Posted in Industry News
-
22nd Oct 2019
-
News from Merck
-
-
An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity
-
Posted in Rehabilitation Articles
-
01st Oct 2019
-
Rachel Farrell and David Baker
-
-
New data from Biogen reinforce long-term benefits of Tecfidera® (Dimethyl Fumarate) over 10 years
-
Posted in Industry News
-
13th Sep 2019
-
News from Biogen at #ECTRIMS19
-
-
New Real-World Data Support Long-Term Efficacy and Safety Profile of MAVENCLAD®
-
Posted in Industry News
-
13th Sep 2019
-
News of Mavenclad from #ECTRIMS19
-
-
NHS Ayrshire & Arran launch campaign on World MS Day calling on people with MS to seek regular support from services
-
Posted in Industry News,News Review
-
30th May 2019
-
Campaign to encourage interaction of PwMS with services
-
-
Clinical perspectives on MAVENCLAD® (cladribine 10mg tablets), for highly active relapsing multiple sclerosis (MS), and real-world experiences from members of the multidisciplinary MS team
-
Posted in Sponsored Feature,Supplements
-
07th May 2019
-
This article was initiated, developed and funded by Merck
-
-
Modern Thinking in MS Management
-
Posted in Courses & Conferences
-
04th Mar 2019
-
Preview: n educational meeting organised and funded by Teva UK Limited, open to Consultants, Nurses and Specialist Registrars with an interest in Multiple Sclerosis
-
-
The Missing Pieces: Identifying the gaps in care and conversations in MS
-
Posted in Online First,Special Feature,Sponsored Feature
-
10th Jul 2017
-
Developed and funded by Sanofi Genzyme
-
-
The Clinical Implications from the First Hundred Known MS Susceptibility Genes
-
Posted in Clinical Review Article
-
18th Jun 2014
-
David Booth